NEW YORK ( TheStreet) -- AstraZeneca ( AZN - Get Report) said late Wednesday it would discontinue the development of Certriad, a treatment for mixed dyslipidemia, with Abbott ( ABT - Get Report). The co-development and license agreement with Abbott will end on Jan. 22, 2011, AstraZeneca said. The companies reached the decision after reviewing a complete response letter for Certriad from the Food and Drug Administration in March and determining that the drug's development was "no longer commercially attractive." Abbott said the decision would have no financial impact on its ongoing per-share earnings in 2010 or 2011. -- Written by Joseph Woelfel >To contact the writer of this article, click here: Joseph Woelfel >To submit a news tip, send an email to: firstname.lastname@example.org.